Merck 2010 Annual Report Download - page 173
Download and view the complete annual report
Please find page 173 of the 2010 Merck annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
-
78
-
79
-
80
-
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
-
116
-
117
-
118
-
119
-
120
-
121
-
122
-
123
-
124
-
125
-
126
-
127
-
128
-
129
-
130
-
131
-
132
-
133
-
134
-
135
-
136
-
137
-
138
-
139
-
140
-
141
-
142
-
143
-
144
-
145
-
146
-
147
-
148
-
149
-
150
-
151
-
152
-
153
-
154
-
155
-
156
-
157
-
158
-
159
-
160
-
161
-
162
-
163 -
164 -
165 -
166 -
167 -
168 -
169 -
170 -
171 -
172 -
173 -
174 -
175 -
176 -
177 -
178 -
179 -
180 -
181 -
182 -
183 -
184
-
185
-
186
-
187
-
188
-
189
-
190
-
191
-
192
-
193
-
194
-
195
-
196
-
197
-
198
-
199
-
200
-
201
-
202
-
203
-
204
-
205
-
206
-
207
-
208
-
209
-
210
-
211
-
212
-
213
-
214
-
215
-
216
-
217
-
218
-
219
-
220
-
221
-
222
-
223
 |
 |
The book values of “Patents, licenses and similar rights, brands, trademarks and other” as well as
goodwill can be attributed to the divisions as follows:
EUR million
Remaining
useful life
in years Merck Serono
Consumer
Health Care
Merck
Millipore
Performance
Materials
Total
Dec. 31,
2010
Total
Dec. 31,
2009
Patents, licenses and similar rights,
brands, trademarks and other
Finite useful life
Rebif ® 11 3,296.5 – – – 3,296.5 3,221.5
Gonal-f ® 8 759.6 – – – 759.6 765.2
Saizen ® 9 276.6 – – – 276.6 275.3
Humira ® 7 257.3 – – – 257.3 267.9
Avonex ® 2.5 120.3 – – – 120.3 152.7
Enbrel ® 2 74.9 – – – 74.9 109.1
Cladribine 10 51.7 – – – 51.7 –
Puregon ® 4 45.8 – – – 45.8 51.3
Technologies 0.5 to 15.5 280.6 3.7 532.0 11.7 828.0 309.2
Brands 4.75 to 13.5 1.0 16.4 316.9 0.3 334.6 20.5
Customer relationships 0.5 to 16.5 0.8 – 1,518.1 3.2 1,522.1 6.8
Safinamide – 63.4 – – – 63.4 176.8
Cladribine – – – – – – 48.2
Other – 104.4 – 8.7 1.5 114.6 137.4
Intangible assets with an indefinite useful life primarily relate to rights that Merck has acquired
for products or technologies that are still in the research and development stage. Amortization will
only begin once the products start to be marketed.
Company 169Management Report Corporate governance Consolidated Financial Statements
Notes
More information